Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593522 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
A Phase 2 study of MTAP-deleted NSCLC, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06593522: Recruiting Phase 2 study of MTAP-deleted NSCLC, sponsored by Amgen.
NCT06593522 is a Phase 2 study of MTAP-deleted NSCLC that is actively recruiting participants, run by Amgen. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06593522, a Phase 2 study of MTAP-deleted NSCLC, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
Conditions Studied
Interventions
- DRUG AMG 193
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- Valkyrie Clinical Trials - Los Angeles
- University of California Los Angeles - Los Angeles
Texas
- Texas Oncology Central/South Texas - Austin
- Sarah Cannon Research Institute - Dallas
- Texas Oncology - Dallas Fort Worth - Dallas
- US Oncology Research Investigational Products Center - Irving
- Texas Oncology Northeast Texas - Tyler
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
- Hartford HealthCare Cancer Institute - Manchester - Plainville
Michigan
- Trinity Health Saint Joseph Mercy Ann Arbor - Ann Arbor
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
Tennessee
- Sarah Cannon Research Institute Oncology Partners - Nashville
- United States Oncology Regulatory Affairs Corporate Office - Nashville
Colorado
- Rocky Mountain Cancer Centers - Denver
District of Columbia
- Medstar Georgetown University Hospital - Washington D.C.
Louisiana
- Our Lady of the Lake Cancer Institute - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2030-11-29 |
| Phase | Phase 2 |
What NCT06593522 shows while recruiting
NCT06593522 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with MTAP-deleted NSCLC appearing as the primary indexed condition, and to 1 intervention - of which AMG 193 is the first listed.
NCT06593522 names 20 study sites across 9 states, led by California, Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06593522 about?
NCT06593522 is a clinical study titled "A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)". The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
What is the current status of trial NCT06593522?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-12-26. Estimated completion is 2030-11-29.
What conditions does trial NCT06593522 study?
This clinical trial studies the following conditions: MTAP-deleted NSCLC.
What interventions are being tested in trial NCT06593522?
The interventions under investigation include: AMG 193 (DRUG).
Who is sponsoring clinical trial NCT06593522?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06593522 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06593522's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI